 NEW HAVEN, Conn., Feb. 08, 2021 GLOBE NEWSWIRE -- Arvinas, Inc. Nasdaq: ARVN, a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on Thursday, February 11 at 4:30 p.m. ET. 